Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 5.7%

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) shares traded up 5.7% on Friday . The stock traded as high as $50.25 and last traded at $49.77. 294,282 shares traded hands during trading, a decline of 61% from the average session volume of 748,465 shares. The stock had previously closed at $47.08.

Analyst Upgrades and Downgrades

RARE has been the topic of several analyst reports. Wells Fargo & Company began coverage on Ultragenyx Pharmaceutical in a research report on Friday, December 8th. They issued an "overweight" rating and a $72.00 price objective on the stock. JPMorgan Chase & Co. upped their price target on Ultragenyx Pharmaceutical from $88.00 to $92.00 and gave the company an "overweight" rating in a report on Monday, March 18th. Canaccord Genuity Group lifted their price objective on Ultragenyx Pharmaceutical from $110.00 to $111.00 and gave the stock a "buy" rating in a report on Wednesday, February 21st. Robert W. Baird upped their target price on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an "outperform" rating in a research note on Tuesday, January 30th. Finally, Wedbush raised their price target on shares of Ultragenyx Pharmaceutical from $47.00 to $48.00 and gave the company a "neutral" rating in a report on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $91.55.

Ultragenyx Pharmaceutical Stock Performance

The company's 50-day moving average price is $47.59 and its 200 day moving average price is $42.68. The stock has a market cap of $4.13 billion, a PE ratio of -5.99 and a beta of 0.65.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.65) by $0.13. Ultragenyx Pharmaceutical had a negative net margin of 139.70% and a negative return on equity of 369.54%. The company had revenue of $127.39 million during the quarter, compared to analyst estimates of $119.38 million. During the same period in the previous year, the business posted ($2.16) earnings per share. The firm's quarterly revenue was up 23.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.34 earnings per share for the current fiscal year.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, Director Matthew K. Fust sold 12,195 shares of Ultragenyx Pharmaceutical stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $50.88, for a total transaction of $620,481.60. Following the transaction, the director now directly owns 14,860 shares in the company, valued at $756,076.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Karah Herdman Parschauer sold 3,756 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $53.76, for a total value of $201,922.56. Following the completion of the sale, the executive vice president now directly owns 67,340 shares of the company's stock, valued at $3,620,198.40. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 12,195 shares of the firm's stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $50.88, for a total transaction of $620,481.60. Following the sale, the director now owns 14,860 shares in the company, valued at $756,076.80. The disclosure for this sale can be found here. Insiders sold 31,974 shares of company stock worth $1,639,721 in the last three months. Corporate insiders own 6.80% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Covestor Ltd grew its holdings in Ultragenyx Pharmaceutical by 392.1% during the 3rd quarter. Covestor Ltd now owns 748 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 596 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Ultragenyx Pharmaceutical by 118.8% in the fourth quarter. UMB Bank n.a. now owns 606 shares of the biopharmaceutical company's stock worth $29,000 after buying an additional 329 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Ultragenyx Pharmaceutical by 622.3% during the first quarter. GAMMA Investing LLC now owns 1,004 shares of the biopharmaceutical company's stock worth $47,000 after acquiring an additional 865 shares during the last quarter. Lazard Asset Management LLC grew its stake in Ultragenyx Pharmaceutical by 36.6% during the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 240 shares in the last quarter. Finally, Comerica Bank increased its holdings in Ultragenyx Pharmaceutical by 24.7% in the 4th quarter. Comerica Bank now owns 1,331 shares of the biopharmaceutical company's stock valued at $64,000 after acquiring an additional 264 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.